Mattias Münnich

Atley’s automated production module allows for a standardised and reproducible production of the pharmaceuticals used in Targeted Alpha Therapy, a promising treatment for disseminated cancer. The module will enhance clinical research in this field and is essential in order to enable the future treatment of cancer patients using this method. Targeted Alpha Therapy has the potential to improve and save millions of lives. For this to happen, Atley's technology is needed.

Ziccum's ambient drying technology LaminarPace opens up unique thermostable formulation possibilities for next-generation biomolecules - from vaccines to protein therapeutics.

Mevia provides intelligent solutions to increase the quality of medical treatments. We develop solutions for improving adherence - the greatest challenge in medical treatments. We manage to do this by increasing the patient support and providing personal adherence feedback in real-time. We work closely with our clients to develop innovative packaging and IT solutions that provide patients with the best possible experience.

Atley’s automated production module allows for a standardised and reproducible production of the pharmaceuticals used in Targeted Alpha Therapy, a promising treatment for disseminated cancer. The module will enhance clinical research in this field and is essential in order to enable the future treatment of cancer patients using this method. Targeted Alpha Therapy has the potential to improve and save millions of lives. For this to happen, Atley's technology is needed.

Ziccum's ambient drying technology LaminarPace opens up unique thermostable formulation possibilities for next-generation biomolecules - from vaccines to protein therapeutics.

Chalmers Ventures is a leading Tech Investor and Venture Builder in the Nordics, dedicated to creating global growth companies and taking new technology from lab to market. Focus is on university spin-outs and deep tech. We employ a unique dual approach that integrates venture creation with tech investments, harnessing the potential of new research and deep tech within Chalmers. Our expertise lies in initiating and nurturing companies from groundbreaking research, ensuring a robust pipeline of high-quality ventures in which we invest and act as active owners. Our involvement extends through the entire company lifecycle until exit, with the aim to generate substantial business success and make a positive global impact.

Mevia provides intelligent solutions to increase the quality of medical treatments. We develop solutions for improving adherence - the greatest challenge in medical treatments. We manage to do this by increasing the patient support and providing personal adherence feedback in real-time. We work closely with our clients to develop innovative packaging and IT solutions that provide patients with the best possible experience.